The Philippine ingredients maker has left its capex headache behind. Now comes the harder problem: selling more. For much of the past few years, investors in D&L Industries had a simple question: when would the Batangas plant stop consuming capital and start producing returns? In the first quarter of 2026, the answer became clearer. The new facility, once the centerpiece of a heavy investment cycle and a drag on financial ratios, has now logged its sixth consecutive profitable quarter . Capital spending, no longer the main strain on the balance sheet, has faded from the foreground. But business stories rarely end when construction does. With the plant finally contributing, a more prosaic but more important question has taken its place: can D&L grow revenues again? The company’s first-quarter results offered a study in contrasts. Net income rose 5% year on year to ₱716.7m , a respectable showing in a volatile environment. Gross margin improved to 13.4% , from 12.7% a year...
The Philippine specialty manufacturer had a banner year for sales. The harder question is whether those sales can again be converted into cash. In most years, a 36% jump in revenue would be cause for uncomplicated celebration. At D&L Industries , a Philippine maker of food ingredients, oleochemicals, specialty plastics, and outsourced consumer products, sales rose to ₱55.39bn in 2025 , from ₱40.67bn a year earlier. Net income rose too, by 11% to ₱2.59bn . The trouble is that the top line grew much faster than the profit line. Gross profit increased by only 15% to ₱7.21bn , a respectable showing but one that betrayed the nature of the boom: part volume, part pricing, part inflation. D&L sold more, but it also sold costlier molecules. That makes 2025 a useful year for understanding D&L’s business. The company is not a typical consumer manufacturer with brands on supermarket shelves. It is more often hidden inside other firms’ products: the fat in a noodle, the ingredient in ...